
样式: 排序: IF: - GO 导出 标记为已读
-
Genetics of irritable bowel syndrome: shifting gear via biobank-scale studies Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-08-10 Michael Camilleri, Alexandra Zhernakova, Isotta Bozzarelli, Mauro D’Amato
-
Gut immune cell trafficking: inter-organ communication and immune-mediated inflammation Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-08-09 Sebastian Zundler, Claudia Günther, Andreas E. Kremer, Mario M. Zaiss, Veit Rothhammer, Markus F. Neurath
-
Stigma: a major barrier to hepatitis B elimination Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-08-03 Thomas Tu
Advances in hepatitis B management are still not reaching most of the affected community. A major barrier to this translation is stigma. Research and clinical communities have a responsibility to mitigate stigma and ensure that the voices of the affected community are considered in decision-making conversations.
-
The metabolic nature of inflammatory bowel diseases Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-07-29 Timon E. Adolph, Moritz Meyer, Julian Schwärzler, Lisa Mayr, Felix Grabherr, Herbert Tilg
-
Hepatitis D virus: more attention needed. Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-07-26 Maria Buti
-
Positive phase III results for odevixibat for progressive familial intrahepatic cholestasis. Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-07-25 Katrina Ray
-
Fazirsiran shows promise for liver disease in AAT. Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-07-25 Katrina Ray
-
No increased risk of acute liver injury after COVID-19 vaccination. Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-07-25 Katrina Ray
-
Saliva - a new route for enteric viruses. Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-07-25 Katrina Ray
-
A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-07-20 Anna Kramvis, Kyong-Mi Chang, Maura Dandri, Patrizia Farci, Dieter Glebe, Jianming Hu, Harry L. A. Janssen, Daryl T. Y. Lau, Capucine Penicaud, Teresa Pollicino, Barbara Testoni, Florian Van Bömmel, Ourania Andrisani, Maria Beumont-Mauviel, Timothy M. Block, Henry L. Y. Chan, Gavin A. Cloherty, William E. Delaney, Anna Maria Geretti, Adam Gehring, Kathy Jackson, Oliver Lenz, Mala K. Maini, Veronica
-
Benign liver tumours: understanding molecular physiology to adapt clinical management Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-07-14 Jean-Charles Nault, Valérie Paradis, Maxime Ronot, Jessica Zucman-Rossi
-
Black voices in gastroenterology and hepatology Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-07-08 Joan A. Culpepper-Morgan, Alexandra Guillaume, Jeremy Louissaint, Renee Williams
The Association of Black Gastroenterologists and Hepatologists (ABGH) was established to improve health equity in Black communities and to provide academic and social support for Black gastroenterologists and hepatologists. In this Viewpoint, four members of ABGH (early career, mid-career and late career) discuss their route into gastroenterology and hepatology, how academia and medicine can promote
-
Author Correction: Current and future colorectal cancer screening strategies. Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-08-01 Aasma Shaukat,Theodore R Levin
-
'Dark matter' beyond the bacteria in faecal microbiota transplantation. Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-07-04 Tao Zuo
-
Sudden onset hepatitis in children Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-07-01 Deirdre A. Kelly, Zania Stamataki
-
Mapping the malignant transformation from polyps to CRC. Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-08-01 Katrina Ray
-
Liver preserved ex situ for 3 days transplanted into patient. Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-08-01 Jordan Hindson
-
Proteomics and machine-learning models for alcohol-related liver disease biomarkers. Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-08-01 Jordan Hindson
-
Tirzepatide to treat obesity: phase III results. Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-08-01 Jordan Hindson
-
Adjuvant chemotherapy guided by circulating tumour DNA in stage II colon cancer. Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-08-01 Jordan Hindson
-
Gut bacteria go on record Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-06-28 Alexander Crits-Christoph, Jotham Suez
-
Ten steps to eliminating hepatitis C in hospitals Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-06-23 José Luis Calleja, Antonio Aguilera, Maria Buti, Javier Crespo, Federico García, Francisco Jorquera, Luis Enrique Morano, Juan Macias, Jeffrey V. Lazarus
Only 12 high-income countries are on track to meet the World Health Organization’s goal of eliminating hepatitis C as a public health threat by 2030, and micro-elimination opportunities in high-risk populations in settings such as hospitals are often overlooked. We propose ten steps to eliminate hepatitis C in hospitals.
-
Depression and anxiety in inflammatory bowel disease: epidemiology, mechanisms and treatment Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-06-22 Tania H. Bisgaard, Kristine H. Allin, Laurie Keefer, Ashwin N. Ananthakrishnan, Tine Jess
-
GLP1-mediated gut-brain neural circuit controls appetite suppression. Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-08-01 Katrina Ray
-
Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-06-16 Mohammed Eslam, Hashem B. El-Serag, Sven Francque, Shiv K. Sarin, Lai Wei, Elisabetta Bugianesi, Jacob George
Metabolic (dysfunction)-associated fatty liver disease (MAFLD) affects up to a third of the global population; its burden has grown in parallel with rising rates of type 2 diabetes mellitus and obesity. MAFLD increases the risk of end-stage liver disease, hepatocellular carcinoma, death and liver transplantation and has extrahepatic consequences, including cardiometabolic disease and cancers. Although
-
Hepatitis C testing, treatment and prevention in low- and middle-income country prisons Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-06-15 Joseph D. Tucker, Ahsan Ahmad, Andargachew Mulu, Monde Muyoyeta, Muhammad Radzi Abu Hassan, Adeeba Kamarulzaman
Hepatitis C virus (HCV) infection is common among people who are incarcerated in low- and middle-income countries. Prison policy changes towards HCV testing and treatment are pivotal for social justice and can be a crucial step for achieving HCV global elimination targets.
-
Specific gut microbiota taxa as a key source of variability in colitis model Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-06-14 Nicolas Benech, Harry Sokol
Owing to its simplicity, dextran sulfate sodium (DSS)-induced colitis is one of the most widely used mouse models of colitis. However, the severity of inflammation varies from one experiment to another. In a new study, Forster and colleagues have provided new insights into the DSS model by revealing specific microbial taxa that underlie disease variability.
-
Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-06-08 Philip Johnson, Qing Zhou, Doan Y Dao, Y. M. Dennis Lo
Hepatocellular carcinoma (HCC) is one of the most prevalent and lethal causes of cancer-related death worldwide. The treatment of HCC remains challenging and is largely predicated on early diagnosis. Surveillance of high-risk groups using abdominal ultrasonography, with or without serum analysis of α-fetoprotein (AFP), can permit detection of early, potentially curable tumours, but is limited by its
-
Mechanisms and pathophysiology of Barrett oesophagus Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-06-07 Rhonda F. Souza, Stuart J. Spechler
Barrett oesophagus, in which a metaplastic columnar mucosa that can predispose individuals to cancer development lines a portion of the distal oesophagus, is the only known precursor of oesophageal adenocarcinoma, the incidence of which has increased profoundly over the past several decades. Most evidence suggests that Barrett oesophagus develops from progenitor cells at the oesophagogastric junction
-
Prognostic potential of repeated faecal haemoglobin levels in CRC detection. Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-07-01 Katrina Ray
-
Promising phase I interim results for CAR T cells in gastrointestinal cancers. Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-07-01 Katrina Ray
-
Crosstalk between enteric neurons and colorectal cancer stem cells influences self-renewal. Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-07-01 Katrina Ray
-
Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-05-31 Patrice D. Cani, Clara Depommier, Muriel Derrien, Amandine Everard, Willem M. de Vos
Ever since Akkermansia muciniphila was discovered and characterized two decades ago, numerous studies have shown that the lack or decreased abundance of this commensal bacterium was linked with multiple diseases (such as obesity, diabetes, liver steatosis, inflammation and response to cancer immunotherapies). Although primarily based on simple associations, there are nowadays an increasing number of
-
CRC inhibited by the ketone body β-hydroxybutyrate. Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-07-01 Jordan Hindson
-
Sex bias in clinical trials in gastroenterology and hepatology Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-05-24 Patrizia Burra, Alberto Zanetto, Giacomo Germani
Biological sex bias in clinical trials is a common issue in various medical fields, including gastroenterology and hepatology. Without sex parity and increased attention to sex-specific analyses, the translation of trial results into real-world clinical practice remains suboptimal with unpredictable consequences for patient care.
-
Breakthroughs in hepatitis C research: from discovery to cure Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-05-20 Michael P. Manns, Benjamin Maasoumy
In the 1970s, an unknown virus was suspected for documented cases of transfusion-associated hepatitis, a phenomenon called non-A, non-B hepatitis. In 1989, the infectious transmissible agent was identified and named hepatitis C virus (HCV) and, soon enough, the first diagnostic HCV antibody test was developed, which led to a dramatic decrease in new infections. Today, HCV infection remains a global
-
Jumping the chasm from postdoc to PI Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-05-20 Alyce M. Martin
The transition from postdoc to PI is one filled with excitement, anticipation and empowerment, with moments of self-doubt and imposter syndrome thrown in for good measure. Relatively few postdocs successfully cross this chasm, making it even more important to nurture those who do.
-
Achieving health equity in liver disease pharmacotherapy Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-05-17 Ani Kardashian, Lauren D. Nephew
New data demonstrate racial and ethnic disparities in access to prescription medications in persons with chronic liver disease in the USA. Here, we discuss potential health equity solutions that address structural and social determinants of health to mitigate liver health inequities in access to liver disease pharmacotherapies.
-
Dietary management of adults with IBD — the emerging role of dietary therapy Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-05-16 Jessica A. Fitzpatrick, Sarah L. Melton, Chu Kion Yao, Peter R. Gibson, Emma P. Halmos
Historically, dietitians played a minor part in the management of inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis. Patients were commonly referred for consequences of uncontrolled disease, such as malnutrition and bowel obstruction risk. Today, dietitians are fundamental members of the multidisciplinary IBD team, from educating on the role of diet at diagnosis and
-
Genetics, pathobiology and therapeutic opportunities of polycystic liver disease Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-05-13 Paula Olaizola, Pedro M. Rodrigues, Francisco J. Caballero-Camino, Laura Izquierdo-Sanchez, Patricia Aspichueta, Luis Bujanda, Nicholas F. Larusso, Joost P. H. Drenth, Maria J. Perugorria, Jesus M. Banales
Polycystic liver diseases (PLDs) are inherited genetic disorders characterized by progressive development of intrahepatic, fluid-filled biliary cysts (more than ten), which constitute the main cause of morbidity and markedly affect the quality of life. Liver cysts arise in patients with autosomal dominant PLD (ADPLD) or in co-occurrence with renal cysts in patients with autosomal dominant or autosomal
-
A link to the past Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-05-11
Having a sense of the history of research and clinical practice is valuable. With that in mind, we now publish Journal Club articles that focus on historical papers that are of particular significance, a link from past to present.
-
Regulating protease homeostasis in irritable bowel syndrome. Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-07-01 Katrina Ray
-
Current and future colorectal cancer screening strategies Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-05-03 Aasma Shaukat, Theodore R. Levin
Despite strong evidence of effectiveness, colorectal cancer (CRC) screening remains underused. Currently, there are several options for CRC screening, each with its own performance characteristics and considerations for practice. This Review aims to cover current CRC screening guidelines and highlight future blood-based and imaging-based options for screening. In current practice, the leading non-invasive
-
Perianal fistula surgical closure in Crohn's disease. Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-06-01 Eleni Kotsiliti
-
Danger! P2Y14 receptor links cell death to liver fibrosis. Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-06-01 Katrina Ray
-
The gut microbiome as a modulator of healthy ageing Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-04-25 Tarini Shankar Ghosh, Fergus Shanahan, Paul W. O’Toole
The gut microbiome is a contributory factor in ageing-related health loss and in several non-communicable diseases in all age groups. Some age-linked and disease-linked compositional and functional changes overlap, while others are distinct. In this Review, we explore targeted studies of the gut microbiome of older individuals and general cohort studies across geographically distinct populations. We
-
Capturing the environment of the Clostridioides difficile infection cycle Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-04-25 Matthew K. Schnizlein, Vincent B. Young
Clostridioides difficile (formerly Clostridium difficile) infection is a substantial health and economic burden worldwide. Great strides have been made over the past several years in characterizing the physiology of C. difficile infection, particularly regarding how gut microorganisms and their host work together to provide colonization resistance. As mammalian hosts and their indigenous gut microbiota
-
Mechanisms of mucosal healing: treating inflammatory bowel disease without immunosuppression? Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-04-19 Eduardo J. Villablanca, Katja Selin, Charlotte R. H. Hedin
Almost all currently available treatments for inflammatory bowel disease (IBD) act by inhibiting inflammation, often blocking specific inflammatory molecules. However, given the infectious and neoplastic disease burden associated with chronic immunosuppressive therapy, the goal of attaining mucosal healing without immunosuppression is attractive. The absence of treatments that directly promote mucosal
-
Hepatic IRF3 in glucose intolerance Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-04-20 Eleni Kotsiliti
-
Gemcitabine and cisplatin plus immunotherapy in advanced biliary tract cancer: a phase II study. Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-05-01 Jordan Hindson
-
Bile acid metabolites produced by gut bacteria suppress TH17 cells. Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-05-01 Jordan Hindson
-
Toripalimab and chemotherapy in oesophageal squamous cell carcinoma. Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-05-01 Jordan Hindson
-
Gastrointestinal post-acute COVID-19 syndrome Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-04-05 Hadar Meringer, Saurabh Mehandru
The definition of gastrointestinal involvement in post-acute COVID-19 syndrome, its frequency and its pathophysiology are still not completely understood. Here, we discuss the emerging evidence supporting immunological signatures and the unique nature of the gastrointestinal tract in this syndrome.
-
Fungal strain-dependent inflammation in IBD Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-04-04 Eleni Kotsiliti
-
The tumour-associated microbiome Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-03-31 Christopher D. Johnston, Susan Bullman
The burgeoning field of intratumoural microbiome research has been driven by advances in next-generation sequencing technologies, with compelling evidence on the role of the microbiota in cancer initiation, progression and patient response to treatment. Here, we discuss new concepts of the tumour-associated microbiota and what is needed to advance the translational impact of these findings in gastrointestinal
-
Bench to bedside — new insights into the pathogenesis of necrotizing enterocolitis Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-03-28 David J. Hackam, Chhinder P. Sodhi
Necrotizing enterocolitis (NEC) is the leading cause of death and disability from gastrointestinal disease in premature infants. Recent discoveries have shed light on a unifying theorem to explain the pathogenesis of NEC, suggesting that specific treatments might finally be forthcoming. A variety of experiments have highlighted how the interaction between bacterial signalling receptors on the premature
-
Multiomics to elucidate inflammatory bowel disease risk factors and pathways Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-03-17 Manasi Agrawal, Kristine H. Allin, Francesca Petralia, Jean-Frederic Colombel, Tine Jess
Inflammatory bowel disease (IBD) is an immune-mediated disease of the intestinal tract, with complex pathophysiology involving genetic, environmental, microbiome, immunological and potentially other factors. Epidemiological data have provided important insights into risk factors associated with IBD, but are limited by confounding, biases and data quality, especially when pertaining to risk factors
-
Pancreatic cancer: why the cell of origin matters. Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-05-01 Julia Mayerle
-
COVID-19 and liver disease: where are we now? Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-03-17 Francesco Paolo Russo, Patrizia Burra, Alberto Zanetto
Patients with end-stage liver disease and COVID-19 are at a higher risk of hospitalization, ventilation and death than those without chronic liver disease. Whether the aetiology of liver disease also affects the natural history of COVID-19 in cirrhosis is debated. Effective and universal vaccination is paramount to combat SARS-CoV-2 infection.
-
Immunosuppressive IBD drugs and COVID-19 vaccine immunogenicity. Nat. Rev. Gastroenterol. Hepatol. (IF 73.082) Pub Date : 2022-04-01 Jordan Hindson